Cardiac Monitors

VectraCor designs and manufactures portable diagnostic medical devices that enable primary care, urgent care, and telemedicine environments to perform cardiac and pulmonary testing. The company specializes in ECG systems, Holter monitoring, and spirometry platforms that integrate with standard tablets and laptops, reducing infrastructure costs while maintaining clinical-grade diagnostics. The VectraplexECG system uses patented 5-electrode technology to derive 15–22 lead ECG traces and detect changes suggestive of acute coronary events via the proprietary Cardiac Electrical Biomarker (CEB®). The V300 Holter monitor provides continuous ambulatory cardiac monitoring with cloud-based data transfer and EMR integration. The Orbit™ Spirometer delivers pulmonary function testing with mobile deployment. All devices are FDA-cleared, CE-marked, and manufactured under ISO 13485 certification. VectraCor products emphasize durable, portable design for point-of-care diagnostics and remote monitoring workflows, with integrated EMR connectivity to major health systems and email-based report distribution.

SCHILLER Americas is a cardiopulmonary diagnostic device manufacturer with over 50 years of innovation in the industry. The company specializes in electrocardiography (EKG/ECG), patient monitoring systems, lung function testing equipment, and integrated diagnostic workstations. Their product portfolio includes ECG systems, diagnostic stations (such as the DS-20), spirometry and body plethysmography systems (including TremoFlo), and patient vital signs monitoring devices. SCHILLER Americas serves multiple market segments including general practice, hospitals, lung function laboratories, and government/institutional customers. The company emphasizes integration of device hardware with proprietary diagnostic software and user interface design, operating under the philosophy of "The Art of Diagnostics." Products are designed for clinical environments ranging from primary care to specialized pulmonary function testing laboratories. The company operates a trial program allowing healthcare facilities to evaluate devices before purchase. Manufacturing and distribution capabilities support the US market through their Americas division. While specific FDA 510(k) or ISO certifications are not detailed on the homepage, the clinical focus and regulatory positioning suggest standard medical device compliance standards are maintained.

BRAEBON MEDICAL CORP. is a Canadian manufacturer of polysomnography (PSG) sensors, home sleep testing (HST) systems, sleep diagnostic devices, and dental sleep medicine solutions. Over 20 years, the company has developed a portfolio of over 140 products serving sleep labs, cardiologists, dentists, and home-based sleep disorder screening. Core product lines include the MediByte and MediByte Jr. Level 3/4 portable sleep recorders, DentiTrac oral appliance compliance monitoring technology, and an extensive range of PSG sensors including airflow, nasal pressure, and thermistor sensors. BRAEBON also offers cloud-based workflow management software for intake-to-treatment coordination and disposable sensor alternatives. The company serves international markets across six continents. All products comply with U.S. FDA, Health Canada, European CE, IEC 60601, and Australian TGA standards. BRAEBON holds ISO 13485 certification and CE marking. The company emphasizes rapid technical support, industry-leading warranties, and equipment replacement programs. Primary markets include sleep medicine laboratories, hospital cardiology departments screening for sleep apnea, and dental professionals monitoring oral appliance therapy effectiveness. Manufacturing is conducted in Canada.

Great Lakes NeuroTechnologies (GLNT) is a biomedical technology company specializing in physiological monitoring systems and patient-centered diagnostic platforms for movement disorders, telemedicine, and in-home health monitoring. Founded in 2010 and based in Independence, Ohio, GLNT designs, manufactures, and distributes wireless and web-based bioinstrumentation products for clinical, research, and educational applications. The company's primary offerings include the Kinesia line of wearable systems for real-time motor symptom assessment in Parkinson's disease and essential tremor, and the BioRadio wireless data acquisition platform for research and education. GLNT holds over 50 patents in neurological and movement disorder monitoring, with recent innovations in AI-driven therapy adjustment and remote deep brain stimulation (DBS) programming. The company serves physicians, medical technicians, healthcare practitioners, researchers, universities, and hospitals, addressing clinical needs in remote patient monitoring, clinical trial management, and therapy optimization.

ATC Technologies Inc is an ISO 13485 certified medical device manufacturer based in Wilmington, Massachusetts, specializing in contract manufacturing and design of surgical instruments and diagnostic devices since 1989. The company develops electrocautery instruments, biopsy forceps, laparoscopy tools, pencil electrodes, and handheld electrode probes for surgical and cardiology applications. ATC provides end-to-end services from clinical need definition through design, FDA-regulated testing, approval, manufacturing, and distribution, with a focus on quality assurance, enhanced performance, and patient care outcomes. The company serves as an OEM manufacturer and partner for medical device innovation.

LD Technology LLC is a Miami-based medical device manufacturer specializing in non-invasive diagnostic systems for chronic disease complication detection and management. The company designs and markets FDA-cleared devices for vascular function assessment and autonomic nervous system (ANS) evaluation, with particular focus on early detection of diabetes-related complications including peripheral artery disease, endothelial dysfunction, cardiac autonomic neuropathy, and sudomotor function impairment. LD Technology's integrated product suite combines hardware devices with cloud-based data management and clinical analytics software (HIPAA-compliant, ISO 27001-certified), enabling physicians to rapidly assess and monitor vascular and autonomic health in clinic and hospital settings. Products include the TM-Flow/CCS platform for comprehensive vascular and ANS assessment, the Lifeprobes Kiosk for pre-consultation vital sign capture and patient registration, the TBL-ABI for ankle-brachial index measurement, the OXI_W for cardiac autonomic nervous system assessment, and the SWEATC for sudomotor function evaluation. The company emphasizes ease of use, rapid data capture, non-invasive testing methodologies, and seamless integration into existing clinical workflows.

Medtronic is a global healthcare technology leader serving 79+ million patients across diagnostic imaging, surgical and operating room equipment, intensive care, specialty medical, and homecare sectors. The company manufactures and distributes a comprehensive portfolio spanning cardiac rhythm and diagnostics systems, pacemakers, implantable cardioverter-defibrillators, deep brain stimulation devices, robotic surgery platforms, ventilators, anesthesia machines, infusion pumps, continuous glucose monitoring systems, insulin pumps, endoscopic and surgical navigation systems, and wound closure products. Recent FDA clearances include the Stealth AXiS surgical system for spine surgery and pulsed field ablation (PFA) technologies for atrial fibrillation treatment. Medtronic serves hospitals, surgical centers, critical care units, interventional labs, and home care settings through product lines in cardiac, vascular, neuromodulation, minimally invasive surgery, respiratory, and diabetes management. The company conducts 170+ active clinical trials, invests $2.7B annually in R&D, and holds FDA 510(k) clearances, CE marks, and ISO 13485 certification. Manufacturing and distribution capabilities span North America, Europe, and international markets with customer support available 24/7.

Medicalgorithmics S.A. is a Warsaw-based, publicly listed (GPW) medical technology company founded in 2005, specializing in AI-powered, noninvasive cardiac diagnostic solutions. The company develops and manufactures a comprehensive suite of ECG monitoring devices and cloud-based software platforms that leverage advanced artificial intelligence to detect, classify, and analyze cardiac arrhythmias. Key product offerings include PocketECG (full-disclosure mobile cardiac telemetry with rich diagnostic reporting), Kardiobeat.ai (wearable 24–18 day Holter monitor with AI-driven analysis), DeepRhythm Platform (DRP) – a hardware-agnostic cloud ECG platform with FDA clearance and Health Canada licensing – DeepRhythmAI (DRAI) for rapid arrhythmia detection across third-party devices, and Virtual Cardiac Stress Test (VCAST), an advanced CT-based diagnostic tool for coronary artery assessment. All core products carry FDA 510(k) clearance, EU MDR certification, and Health Canada approval. The company serves cardiologists, healthcare systems, and clinical research organizations across North America, Europe, and Asia-Pacific, with an extensive annotated heartbeat library supporting over 100 arrhythmia types. Medicalgorithmics also provides R&D services, clinical trial support, and scientific research partnerships focused on cardiovascular disease diagnosis.

Caregility Corporation is an enterprise telehealth and virtual care platform provider serving healthcare systems, hospitals, and care facilities across inpatient, outpatient, and home settings. Founded in 2011, the company delivers the Caregility Connected Care™ Platform, a cloud-based ecosystem that integrates AI-powered clinical workflows, virtual nursing, bedside sensors, and secure video collaboration tools. The platform enables virtual care delivery across emergency departments, ICUs, operating rooms, observation units, behavioral health, neonatal care, and long-term care environments. With deployments in over 1,100 hospitals across 85+ health systems, Caregility facilitates more than 6 million virtual sessions annually. The platform addresses critical healthcare challenges including clinician shortages, geographic access barriers, and operational inefficiency through features such as real-time clinical collaboration, remote patient monitoring, automated workflow support, and integrated analytics. Caregility emphasizes 99.99% platform availability, HIPAA compliance, ISO 27001/27701 certification, and 24/7 expert support, positioning itself as a mission-critical infrastructure provider for hospital networks seeking to scale virtual care at enterprise scale.

Hearts Bio is a California-based medical device and wellness company offering an integrated ecosystem for health management through diet, fitness, and self-monitoring. The HeartsCare product line comprises portable, Bluetooth-enabled diagnostic meters for at-home testing of cholesterol, glucose, lactate, and ketone levels—each with rapid results and data logging capabilities. HeartsFit provides fitness equipment including performance bicycles. HeartsDiet supplies food weighing scales for dietary tracking. The company also develops HeartsHome, a 3D mobile application (iOS/Android) that aggregates health metrics and test results in an interactive dashboard. HeartsCubeAI represents precision medicine and genomic AI in development. Hearts Bio targets individuals managing chronic disease risk factors (heart disease, diabetes, cancer) and fitness-focused consumers seeking integrated home health monitoring and lifestyle management tools.

MEDICORE Co., Ltd. is a South Korea-based medical device manufacturer specializing in cardiac health and autonomic nervous system assessment. The company develops diagnostic systems for heart rate variability (HRV), accelerated photoplethysmography (APG), and infrared thermography imaging. Their product portfolio serves clinical diagnostics, stress assessment, and cardiovascular health monitoring across hospital, wellness center, and personal health monitoring applications. MEDICORE positions itself as a leader in HRV analysis technology and autonomic nerve function testing, with a focus on transforming lifestyle and preventive healthcare through world-class diagnostic guidance.

Sunset Healthcare Solutions is a Chicago-based manufacturer and wholesale distributor specializing in respiratory-focused medical equipment and consumable supplies for homecare, hospitals, and acute care settings. Founded in 2004, the company offers CPAP therapy equipment, oxygen delivery and concentrator systems, nebulization supplies, tracheostomy care items, suction equipment, and pediatric NIV masks. The company serves home medical equipment suppliers, respiratory specialists, hospitals, acute care facilities, and ambulatory surgery centers through direct sales teams and contracted supplier agreements (Premier, Vizient, ASC). Additional product lines include Breas ventilators, high-flow nasal cannula systems, and OEM repair parts. Sunset maintains manufacturing and distribution operations in Chicago and Elgin, Illinois, and has earned recognition as one of America's Fastest Growing Companies.

CB Innovations (trading as C-Booth Innovations) manufactures the EXG™ wearable ECG platform, an advanced 12-lead continuous cardiac monitoring system designed for rapid deployment in emergency medical services, hospitals, and catheterization labs. Founded by two practicing emergency physicians with over 30 years of combined clinical experience, the company addresses critical gaps in current ECG workflows: electrode misapplication (94.2% rate), diagnostic delays (29% of STEMI patients lack ECG within 10 minutes), and false positives (72% of unnecessary cath lab activations). The EXG™ system enables setup in under 60 seconds with a single connection point, AHA-compliant electrode placement, motion artifact reduction, and expandable 18-lead capability for right-sided and posterior visualization. The platform supports continuous monitoring during imaging, stress testing, and post-ROSC resuscitation, with universal monitor compatibility and seamless EMS-to-ED handoff protocols. FDA-registered and ISO-certified, the device addresses the 2 cm electrode misplacement problem that can obscure ST-segment changes and hide myocardial infarctions.

TransMedics Group, Inc. is a medical technology company headquartered in Andover, Massachusetts, specializing in organ preservation and transplantation. The company manufactures the Organ Care System (OCS)—an FDA-approved, portable ex vivo perfusion platform that maintains donor organs in a near-physiologic state outside the body. TransMedics offers specialized OCS systems for lung, heart, and liver transplantation, addressing critical limitations of traditional cold storage by reducing ischemic injury, improving organ viability assessment, and enabling long-distance organ retrieval. The company also operates the National OCS Program (NOP), providing comprehensive end-to-end technology and clinical support services to transplant centers, including organ procurement logistics, clinical expertise, and resource optimization. Founded in 1998, TransMedics went public in 2019 and has established itself as a leader in transforming transplant outcomes for patients with end-stage organ failure.

HeartBeam, Inc. is a medical technology company specializing in portable, cable-free electrocardiogram (ECG) solutions for ambulatory cardiac monitoring. The company's proprietary Vector Electrocardiography (VECG) technology captures three-dimensional cardiac electrical activity and synthesizes clinical-grade 12-lead ECGs using the HeartBeam AIMIGo device—a credit card-sized, patient-friendly tool. The HeartBeam System integrates a mobile app with cloud-based infrastructure and on-call cardiologist interpretation, enabling patients to record and transmit ECG data from home or any location for rapid clinical review. Founded in 2015 and holding over 20 patents, HeartBeam targets detection and monitoring of cardiac diseases in both professional healthcare and personal-use settings. The system is positioned as an FDA-cleared alternative to traditional in-clinic ECG acquisition, with integration partnerships including HeartNexus for cardiologist networks. Applications span remote patient monitoring, telehealth diagnostics, and at-home arrhythmia detection.

Nova Biomedical is a privately held, globally-leading in vitro diagnostic (IVD) company founded in 1976 and headquartered in Waltham, Massachusetts. The largest privately owned diagnostic company in the United States, Nova Biomedical employs over 1,500 people across manufacturing facilities in Massachusetts and Taipei, Taiwan, serving 110+ countries through its global distributor network. The company specializes in advanced blood testing and analytical instrumentation, with a comprehensive portfolio including critical care blood gas analyzers (StatProfile® Prime series), point-of-care glucose meters (StatStrip®, NovaMax®), cell culture analyzers (BioProfile® Flex), clinical and bioprocessing osmometers, liquid volume verification systems, and automated CSF cell counters. Nova Biomedical serves hospitals, emergency departments, blood banks, biotech/pharmaceutical manufacturers, clinical research laboratories, and veterinary diagnostics markets. The company operates through multiple trusted brand portfolios including Advanced Instruments, BioProfile, StatProfile, StatStrip, Artel, Solentim, and GloCyte, delivering solutions for bioprocessing, clinical diagnostics, and veterinary applications with emphasis on improving patient outcomes and operational efficiency.

Jali Medical is a leading U.S. distributor of neuromodulation devices and wearable neurotechnologies, headquartered in Framingham, Massachusetts. Founded in 1991 with over 30 years of experience, the company specializes in non-invasive brain stimulation systems for neuroscience research and clinical applications. Jali Medical distributes FDA-cleared Transcranial Magnetic Stimulation (TMS) therapy systems for treating Major Depressive Disorder, along with advanced electroencephalography (EEG) systems, transcranial direct current stimulation (tDCS/tACS) devices, electromyography (EMG) systems, and neuronavigation equipment. The company serves academic institutions, research centers, hospitals, and clinicians nationwide, providing precision-engineered neurotechnology coupled with comprehensive scientific support. Jali Medical offers flexible leasing options for TMS therapy systems and in-person product demonstrations to facilitate clinical adoption and research innovation in neurophysiology and behavioral health applications.

R&D Medical Products manufactures skin adhesive interfaces, conductive hydrogels, and finished electronic device assemblies for the wearable medical device market. The company specializes in electrode manufacturing for cardiac monitoring, neonatal applications, and intraoperative nerve monitoring. R&D produces six types of hydrogels including conductive formulations exceeding AAMI EC12 standards, skin surface mount gels, wound care gels, and cosmetic applications. The company also designs and builds custom high-speed production lines including heat sealing equipment, medical pouching systems, corona surface treatment, die cutting and laminating equipment, and peel force testing systems. All manufacturing is USA-based. Founded by Jim Perrault, the creator of hydrogel technology, R&D serves leading medical device OEMs and wearable technology companies.

SmartCardia is a Swiss health technology company offering a comprehensive cardiology and remote patient monitoring solution. The core product is a wearable 7-lead ECG patch—cable-free, waterproof, and reusable—capable of 7–14 day continuous monitoring. All ECG leads and vital signs (respiration, SpO2, activity) stream in near real-time to a cloud-based SaaS platform powered by SmartNeuralNet, a proprietary machine learning engine trained on millions of cardiologist-annotated ECG segments. The platform delivers automated arrhythmia detection, patient deterioration prediction, and full-disclosure ECG analysis, enabling clinicians to transition patients seamlessly between Holter, Extended Holter, Mobile Cardiac Telemetry, and Remote Patient Monitoring without additional visits. FDA-cleared and CE Class IIa approved, SmartCardia serves 100+ hospitals globally with live 24/7 monitoring, immediate clinical notifications, and comprehensive reporting. The solution reduces manual analysis time, lowers staffing costs, and supports continuous care from cardiac screening through post-discharge and long-term monitoring.

ABOUND Diagnostics, Inc. is a San Diego-based in vitro diagnostic (IVD) manufacturer specializing in rapid diagnostic tests and point-of-care testing (POCT) products for both human and veterinary health markets. The company offers a comprehensive portfolio including rapid tests for women's health, drugs of abuse, infectious diseases, tumor markers, and cardiac markers; blood glucose monitoring systems (VivaGuard® Ino, VQ PET H); lancing devices and lancets; infrared thermometers; urinalysis and biochemistry reagent strips; and fluorescence immunoassay (FIA) and chemiluminescence immunoassay (CLIA) test kits. ABOUND serves US and international markets, with a mission to deliver high-quality, affordable diagnostic solutions that improve healthcare access globally.

CardioCommand Inc. is a leading medical technology innovator headquartered in Tampa, Florida, specializing in transesophageal (TAP) pacing and cardiac monitoring devices. Established in 1994, the company delivers minimally invasive cardiac solutions designed for clinicians in cardiology and anesthesia settings. CardioCommand's product portfolio includes transesophageal atrial pacing systems, esophageal catheters, electrode solutions, and noninvasive cardiac monitoring equipment. The company serves major academic medical centers, children's hospitals, and healthcare systems nationwide, supporting both diagnostic and therapeutic cardiac interventions including arrhythmia management, stress testing, and atrial cardioversion. Their TAP technology platform enables safe, easy-to-use cardiac assessment and management with minimal patient invasiveness.

TwinMed LLC is a leading nationwide distributor of medical supplies and solutions serving the post-acute care market, founded in 1998 and headquartered in Santa Fe Springs, California. Operating one of the largest full-line medical supply distribution networks in the United States, TwinMed serves skilled nursing facilities, assisted living communities, home care agencies, and hospice providers. The company maintains strategically positioned distribution centers enabling one-day delivery across 98% of the U.S. market. TwinMed's comprehensive product portfolio includes incontinence management supplies, wound care products, respiratory equipment (ventilators, CPAP machines, oxygen therapy), infection prevention and control solutions, cardiac monitoring systems, mobility and transfer equipment (wheelchairs, walkers, transfer aids), and nutritional supplies. Beyond product distribution, TwinMed provides supply chain optimization, inventory management programs, cost containment services, and clinical support to enhance healthcare facility operational efficiency and patient outcomes. The company emphasizes personalized local service combined with national purchasing power and cost advantages.

Perosphere Technologies is a private medical technology company specializing in coagulation diagnostics and point-of-care testing solutions. The company develops and manufactures the Perosphere ClotChek, a CE-marked pharmacodynamic, reagent-free coagulation assay that provides a global view of coagulation status at the patient bedside. The handheld, battery-powered device delivers lab-precision results within 3-8 minutes with remarkably low variability, enabling rapid clinical decision-making in coagulation management. Perosphere's product portfolio also includes the WBCT Assay (whole blood clotting time assay) with room-temperature storage capability and liquid quality controls for normal and anticoagulated samples. With 16 patents in blood testing and coagulation systems, the company focuses on making diagnosis, treatment, and prevention in coagulation management immediately accessible through actionable data. Positioned as a B2B medical device manufacturer, Perosphere serves clinical laboratories, point-of-care testing environments, and bedside diagnostic needs.

Maguire Enterprises is a medical device interconnection specialist with over 50 years of experience integrating physiologic monitoring and life support equipment across thousands of U.S. hospitals. The company designs and manufactures cables, adapters, multipliers, and integrated solutions that enable seamless compatibility between devices from different manufacturers—particularly for critical care environments such as operating rooms, hybrid ORs, catheterization labs, and ICUs. Core offerings include interconnect cables for ECG and invasive blood pressure (IBP) signal transmission, output multipliers for anesthesia monitors and defibrillators, Device Alarm Nurse Call (DANCE) cables for remote alarm monitoring, and cardiac rhythm management adapters for pacemaker programmers and defibrillators. FDA-regulated, with rapid fulfillment capabilities and deep OEM relationships, Maguire solves interoperability challenges that hospitals and device manufacturers face when deploying multi-vendor monitoring ecosystems.

Biotricity Inc. is a publicly traded medical technology company (NASDAQ-listed, 2021) specializing in remote cardiac monitoring and chronic disease management solutions. Founded in 2010 and headquartered in Redwood City, California, the company develops FDA-cleared wearable cardiac monitoring devices and cloud-based platforms for continuous biometric data collection and analysis. Biotricity's product portfolio includes Bioflux® (mobile cardiac telemetry), Biocore (3-channel ECG Holter monitor with 30-day recording), Bioheart (consumer-grade continuous heart rate monitoring), Biokit (multi-vital remote patient monitoring kit), and Biocare (chronic disease management platform). The company operates a dual-revenue model combining recurring Technology-as-a-Service (TaaS) monitoring fees with device hardware sales. Biotricity serves both clinical providers and direct-to-consumer markets, with trusted monitoring for over 100,000+ patients. The platform emphasizes faster diagnosis (3-5 days vs. 2-3 weeks), wireless data transmission via Bluetooth, and physician-reviewed analysis by cardiologists. Biotricity addresses the growing demand for telehealth and proactive cardiac care management, reducing patient risk and improving clinical outcomes.

Lynn Medical is a family-owned specialty medical distributor based in Wixom, Michigan, with over 56 years of proven expertise serving the healthcare market. Founded in 1966, the company distributes diagnostic supplies and equipment with a focus on cardiology and imaging procedures. Lynn Medical serves more than 2,000 healthcare specialty practices, physician offices, clinics, hospitals, and laboratories nationwide. The company maintains partnerships with over 100 manufacturers and stocks more than 150,000 products, including cardiac catheterization equipment, ECG systems, patient monitoring devices, ultrasound supplies, electrodes, IV and infusion products, PPE, disinfection products, and point-of-care assays. With a team of 30+ clinical professionals offering technical expertise and consultation, Lynn Medical provides comprehensive solutions designed to improve patient management and reduce healthcare costs, backed by competitive pricing, reliable inventory management, and responsive customer service.

Micropace Pty Ltd is a leading medical device manufacturer specializing in cardiac electrophysiology equipment. Founded in 1995 and headquartered in Sydney, Australia, with offices in Santa Ana, California, and Prague, Czech Republic, Micropace distributes its products to over 60 countries worldwide. The company is renowned as the cardiac stimulator of choice for over 65% of EP labs globally. Its flagship product, the EPS320B Cardiac Stimulator, delivers intuitive operation and automation features designed to enhance efficiency in electrophysiology laboratories. Micropace's product portfolio includes OneStim (a portable ECG recorder for rapid arrhythmia diagnosis and management), StimLab, StimCor, OneLink, and specialized adapter cables. The company holds nine patents in electrophysiology and medicine, and partners with industry leaders including GE Healthcare, Boston Scientific, and AtriCure for global distribution. Micropace focuses on delivering quality, reliability, and innovation in cardiac stimulation technology for clinical and research applications.

NeuroMetrix, Inc. is a neurotechnology company specializing in non-invasive medical devices for diagnosing and treating pain and neurological disorders. The company develops point-of-care neuropathy diagnostic tests and FDA-approved wearable neurostimulation devices. Its Quell® platform is a wearable neuromodulator designed for chronic pain management and fibromyalgia symptom reduction. DPNCheck provides rapid nerve conduction testing for peripheral neuropathy evaluation. NeuroMetrix targets healthcare professionals including endocrinologists and podiatrists, as well as direct consumers. Founded in 1996 and based in Woburn, Massachusetts, the company is a wholly-owned subsidiary of electroCore, Inc. and is publicly traded on Nasdaq (NURO). The company emphasizes innovation in digital medicine and neurostimulation through clinical feedback and research.

Princeton BioMeditech Corporation (PBM) is a world leader in rapid, point-of-care diagnostic products. The company manufactures and distributes an extensive portfolio of over 70 different one-step rapid diagnostic tests utilizing patented immunoassay technologies. PBM serves both consumer in-home and professional on-site/point-of-care markets with FDA-cleared and ISO 13485:2016 certified products. Product lines include rapid antigen detection tests for COVID-19/Flu, cardiac markers, infectious disease diagnostics, fertility testing, drugs of abuse screening, tumor markers, and food/environmental pathogen detection. The company offers OEM services, point-of-care analyzer systems, research and development capabilities, and comprehensive product support. Based in Princeton, New Jersey, PBM maintains USA manufacturing operations and serves healthcare providers, clinical laboratories, and consumers globally.

ASCEND Cardiovascular is a specialized cardiovascular IT solutions provider headquartered in Springfield, Illinois. Founded in 1995, the company develops enterprise-grade structured reporting and workflow software designed exclusively for cardiology departments and health systems. The ASCEND CV portfolio delivers multimodality structured reporting capabilities that integrate diagnostic, procedural, and reporting workflows into a unified cardiovascular ecosystem. Core offerings include ASCEND CV (multimodality reporting software), ASCEND InView (zero-footprint DICOM viewer), Gen3Echo (AI-driven echocardiography reporting), ASCEND Analytics (open-schema data warehouse), and Catalyst LIVE (telepresence collaboration platform). The company provides vendor-agnostic solutions with device interfaces, clinical decision support, and implementation services. ASCEND serves leading North American health systems and hospitals, with specialized solutions for pediatric cardiology, congenital heart disease, and non-invasive cardiac imaging. The platform integrates seamlessly with major EHR/HIS systems and medical device manufacturers including Epic, Cerner, GE Healthcare, Philips, and AGFA Healthcare.

Senzime is a medical technology company founded in 1999 and headquartered in Uppsala, Sweden, specializing in advanced patient monitoring and diagnostic systems for anesthesia and acute care. The company's flagship product, TetraGraph, is an electromyography (EMG)-based neuromuscular blockade monitoring system that provides quantitative train-of-four (TOF) monitoring to optimize intubation conditions, neuromuscular block management, and reversal dosing during surgical anesthesia. TetraGraph has been used to monitor over one million patients worldwide and is trusted by thousands of clinicians. The system delivers real-time, objective measurements of neuromuscular function, enabling safer anesthesia practices, improved patient outcomes, and significant operational efficiencies including documented reductions in anesthesia drug spending. Senzime operates globally through direct sales offices in the US, Sweden, and Germany, supported by an extensive network of distributors across Europe, Asia-Pacific, and North America. Listed on NASDAQ Stockholm (ticker: SEZI), Senzime is committed to advancing the standard of care in perioperative monitoring through evidence-based solutions and comprehensive clinical support.

Advanced Instrumentations Inc. is a Miami-based manufacturer and global supplier of high-quality medical equipment, furniture, and advanced medical supplies founded in August 1988. With over three decades of experience and approximately 25-28 employees, the company generates roughly $4 million in annual revenue. Advanced Instrumentations serves hospitals, clinics, and medical facilities worldwide through an extensive network of authorized distributors. The company specializes in a comprehensive range of products including anesthesia machines, patient monitors, hospital beds, defibrillators, surgical tables, ultrasound systems, radiology X-ray equipment, neonatology incubators, operating room fixtures, cardiology equipment, and hospital furniture. Advanced Instrumentations emphasizes superior product quality, outstanding customer service, and excellent technical support, committed to providing reliable and safe solutions for efficient hospital operations and superior patient care.

SeeMedX, Inc. is a medical device company specializing in non-invasive hemodynamic monitoring using proprietary bioimpedance technology. The company develops real-time cardiac monitoring systems designed to detect and prevent acute Congestive Heart Failure (CHF), support chronic heart failure management, and assist in end-stage renal disease monitoring. Their patented impedance cardiography device measures cardiac output, contractility, and thoracic fluid volume non-invasively, enabling healthcare providers to assess patient hemodynamics faster and more accurately than traditional methods. The technology streamlines clinical workflows, reduces intervention time, and improves treatment adjustment accuracy. SeeMedX serves healthcare professionals and provides patient/caregiver education and support. The company maintains HIPAA compliance, engages in clinical research partnerships with academic institutions, and is preparing for U.S. commercial launch following FDA clearance with plans for global expansion.

SafeBeat Rx is a digital health company specializing in AI-powered remote monitoring and therapeutic management for cardiac conditions, particularly atrial fibrillation (AFib) and heart failure. The SafeBeat Platform is a mobile-accessible system featuring proprietary ECG analysis algorithms and AI-driven clinical decision support tools designed for clinicians. The platform integrates data from FDA-cleared cardiac monitoring devices (mobile ECG, mobile cardiac telemetry, and implantable cardiac monitors) to deliver near real-time insights while minimizing alert fatigue. SafeBeat's explainable AI technology goes beyond diagnostics to guide therapeutic interventions, including personalized medication dosing and treatment recommendations. The company, founded in 2020 and led by cardiologist Dr. Rachita Navara and bioengineer Dr. Kunj Patel, focuses on improving healthcare access, reducing costs, and enhancing clinical workflows for cardiac care in hospital and remote monitoring settings.

Nventric is a contract development and manufacturing organization (CDMO) specializing in end-to-end medical device design, development, and manufacturing for the neurovascular, electrophysiology, and coronary markets. The company serves as a strategic partner to medical device OEMs, providing comprehensive solutions from concept through volume production. Nventric's capabilities span innovative design services, advanced prototyping, rigorous testing, clinical design inputs, and full manufacturing support with ISO 13485 certification. The company develops a broad range of interventional devices including revascularization devices, catheters (balloon, guide, aspiration, diagnostic, and ablation), drug-eluting stents, hemostasis valves, and peripherally inserted central catheters (PICCs). Nventric's focus on complex vascular anatomy navigation and energy delivery systems positions it as a specialized partner for treating vascular diseases across multiple clinical applications.

Soulaire Corporation manufactures FDA-cleared Enhanced External Counterpulsation (EECP) circulation enhancement devices for non-surgical cardiovascular wellness, disease prevention, and anti-aging applications. The proprietary system uses sequential pneumatic compression cuffs applied to the calves, thighs, and buttocks, synchronized with patient heartbeat to augment diastolic pressure and promote collateral artery development. Indicated for cardiac conditions including congestive heart failure, angina, coronary artery disease, and peripheral artery disease, as well as stroke recovery, renal dysfunction, diabetes management, and erectile dysfunction. Clinical applications extend to systemic circulation improvement affecting multiple organ systems, lymphatic function, and metabolic health. Distributed exclusively by Soulaire with headquarters in Santa Monica, California.

Implicity is a cloud-based digital MedTech software company specializing in AI-driven remote cardiac monitoring and research solutions for healthcare providers. Founded in 2016, the platform centralizes and standardizes cardiac implantable electronic device (CIED) data from multiple manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic, Microport) into a single unified dashboard. The FDA-cleared, CE-marked platform employs patented AI algorithms to filter clinical alerts, reduce false positives by up to 79%, and prioritize clinically relevant events for faster clinical decision-making. Key solutions include vendor-neutral CIED remote monitoring, ILR ECG Analyzer (for Medtronic implantable loop recorders), AF Alert Management, SignalHF Predictive AI for heart failure risk stratification, and advanced research tools for real-time clinical data collection. The platform demonstrates proven clinical impact: 26% reduction in mortality, 4% reduction in hospitalization length, and 85% reduction in unnecessary atrial fibrillation alerts. Implicity serves over 100,000 patients across more than 250 medical facilities in the United States and Europe, with offices in Cambridge, Massachusetts, and Paris, France.

Wellinks is a virtual-led cardiopulmonary care management platform specializing in chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) management. The company delivers an integrated care model combining remote patient monitoring, virtual pulmonary rehabilitation, personalized clinical coaching, and predictive analytics. Following its acquisition of Spire Health, Wellinks now operates the Spire360 predictive clinical support platform, which continuously monitors respiratory and cardiac metrics using proprietary wearable technology (Spire Tag) and cloud-based analytics. The platform captures 2,000–4,000 breaths per day with 20+ hours median daily wear and predicts clinical deterioration up to 10 days in advance, enabling proactive interventions. Wellinks serves healthcare payers, value-based care organizations, and individual patients, demonstrating significant clinical impact: 16 million COPD-related visit reductions, $30,000 hospitalization cost reduction per patient, and 4% average annual savings. The MySpire patient app and Spire Hub (cellular-connected data hub) provide passive, continuous monitoring without daily user input, supporting long-term adherence critical for chronic disease management.

EpiWatch is an FDA-cleared, prescription-based mobile health platform that delivers real-time tonic-clonic seizure detection and alerting via Apple Watch and iPhone. The AI-powered application runs passively on wearable devices to monitor seizure activity and provides immediate alerts to caregivers when critical events occur, enabling rapid intervention and reducing the risk of Sudden Unexpected Nocturnal Death in Epilepsy (SUDEP). Designed for both pediatric and adult patients with epilepsy, EpiWatch integrates with family sharing and caregiver contact systems, requiring cellular or Wi-Fi connectivity for continuous monitoring. Available by prescription only in the United States at a monthly subscription fee, the platform empowers patients with independence while providing caregivers actionable intelligence during life-threatening events.

brain4care is a medical technology company specializing in non-invasive monitoring of intracranial pressure (ICP) and brain dynamics. The company develops portable, wireless sensors and cloud-based algorithms that enable real-time assessment of ICP variation, intracranial compliance progression, and early detection of intracranial hypertension risk without radiation or invasive procedures. The b4c system is FDA 510(k) cleared and Anvisa certified, designed for deployment in ICU settings, critical care units, and outpatient clinics. The technology supports timely clinical decision-making to prevent brain damage from conditions such as cerebral edema and shunt dysfunction. With over 36,000 patients monitored across 186 active accounts, brain4care's platform delivers immediate digital clinical reports derived from proprietary surrogate ICP waveform analysis. The company collaborates with leading research institutions including Stanford University and the University of Cambridge and maintains ongoing clinical evidence publication.

Eko Health is a digital health company specializing in AI-powered cardiac and pulmonary disease detection and monitoring. The company manufactures FDA-cleared digital stethoscopes and ECG devices that combine high-fidelity audio capture with real-time artificial intelligence algorithms to detect heart murmurs, atrial fibrillation, and reduced ejection fraction. Eko's product ecosystem includes the CORE 500™ Digital Stethoscope with advanced audio processing and noise cancellation, the CORE™ Digital Stethoscope (co-branded with 3M as Littmann® CORE), and the SENSORA® platform for health system integration. The company also offers Eko AI Analysis software for clinical decision support and Eko Telehealth for virtual exam capabilities, deployed in over 800 U.S. hospitals. With more than 700,000 devices sold globally, Eko operates the largest connected digital stethoscope network. The platform is clinically validated across 70+ peer-reviewed publications and holds 9 FDA clearances, with CMS reimbursement established for hospital-based outpatient cardiac screening.

Koven Technology (trading as Hadeco in some markets) is the exclusive North American supplier of vascular Doppler ultrasound systems and related diagnostic equipment. Since 1981, the company has specialized in noninvasive vascular Dopplers for peripheral arterial disease evaluation, surgical Dopplers for intraoperative vascular monitoring, and fetal Dopplers for obstetric monitoring. Their product portfolio includes the Smartdop XT and Smartdop XT6 vascular testing systems, supported by PAUS 2.0 modality worklist software. Koven serves vascular surgeons, cardiologists, obstetricians, and hospital operating rooms with portable and stationary Doppler ultrasound platforms designed for noninvasive diagnosis and real-time intraoperative guidance.

Kentec Medical, established in 1970, is a trusted medical device and supplies manufacturer serving hospitals and healthcare systems across the United States. The company specializes in innovative solutions for blood management, enteral feeding, neonatal care, pharmacy dispensing, and general medical consumables under its proprietary Ameritus™ brand. Key product lines include the SAMMI® closed blood draw and flush sets for safe infusion management, HUMMI® micro-draw blood devices designed to reduce complications in peripheral arterial blood draws, ISOFit™ EN 80369-3 compliant enteral feeding systems, HAVE A HEART® neonatal electrodes, and specialized pharmacy dispensers. Kentec Medical combines clinical expertise with patient-centered design to deliver products that improve outcomes while reducing healthcare costs. The company maintains a strong commitment to clinical education and evidence-based practices, particularly in neonatal intensive care, vascular access, and nutritional support.

Smart-ABI, developed by Hyperion Medical, is a cloud-based diagnostic solution specializing in Ankle Brachial Index (ABI) testing combined with Pulse Volume Recording (PVR) for the rapid, non-invasive diagnosis of Peripheral Artery Disease (PAD) and related vascular conditions. With over 25 years of medical device industry experience, the Smart-ABI platform delivers fast, simple, and accurate vascular assessments that integrate seamlessly into existing electronic medical record systems. The Smart-ABI Hub is a HIPAA-compliant software-as-a-service platform that enables mobile access, collaborative care between providers and specialists, and secure report transmission. The company's comprehensive vascular testing solutions—including the core Smart-ABI device and Smart-LEDA for combined ABI and sudomotor function assessment—are designed to improve early diagnosis of underdiagnosed PAD, reduce major cardiovascular and limb events, and support evidence-based clinical decision-making in diverse care settings.

Solvent Medical is an experienced medical device manufacturer based in Roswell, Georgia, with over 40 years of healthcare industry experience. The company specializes in the design and manufacture of disposable temporary pacing cables for cardiac care applications. Their products are engineered with heavy gauge wiring for enhanced performance and compatibility with most external pacing systems and industry standards. Solvent Medical emphasizes on-demand product delivery, cost-effective solutions, and reliable customer service with worldwide supply chain and distribution capabilities. The company is committed to providing safe, high-quality medical devices that meet stringent healthcare standards.

Beijing Amsino Medical Inc. (美中双和) is a leading Chinese innovative medical device enterprise specializing in cardiovascular interventional products and drug-device combination solutions. Founded in 1999 and headquartered in Beijing's Chaoyang District, the company has established itself as a pioneering developer in cardiac intervention. With over 200 team members and 25 years of brand heritage, Amsino focuses on R&D, manufacturing, and technical service of cardiovascular, cardiac function, and cardiac structural intervention devices. The company holds 40+ patent applications and delivers differentiated product solutions across the broader vascular intervention landscape, including drug-coated stent systems, balloon expansion catheters for both coronary and peripheral applications, and electrophysiology diagnostic catheters. Amsino is recognized as a National-level "Specialized and New Little Giant" enterprise.

Twins & Martin is a leading global distributor of medical devices specializing in endovascular therapy solutions. The company provides a comprehensive portfolio of products spanning peripheral vascular, cardiovascular, venous, and interventional radiology applications, serving healthcare facilities across more than 30 countries for over 30 years. BMC Medical Manufacturing operates as part of Twins & Martin's distribution network, focusing on high-quality medical technology solutions including guide wires, balloon catheters, vascular stents, and catheterization lab equipment. The company emphasizes innovation, quality assurance, regulatory compliance (FCPA, UK Bribery Act), and customer service to support better patient outcomes in endovascular interventional procedures.

ClariPi Inc. is a Seoul-based medical AI software company founded in 2015 specializing in deep-learning powered CT image denoising and diagnostic analysis solutions. The company develops vendor-neutral, FDA-cleared and CE-marked software that enhances CT image clarity while enabling ultra-low-dose imaging protocols across CT scanners from any manufacturer. ClariPi's portfolio includes ClariCT.AI (core denoising engine), ClariPulmo+ (lung nodule detection and COPD analysis), ClariSIGMAM (breast density assessment), ClariAdipo (abdominal fat composition analysis), ClariMetabo (metabolic risk quantification), ClariCardio (coronary artery calcium scoring and CVD risk), ClariOsteo (bone mineral density and fracture risk), and ClariACE (AI contrast enhancement). Products integrate via DICOM protocols with existing PACS systems and clinical workflows, supporting real-time processing from desktop, embedded scanner, or cloud deployment. The company partners with major healthcare systems, OEM CT manufacturers, and imaging centers to reduce radiation exposure while maintaining diagnostic confidence through advanced noise pattern recognition trained on millions of patient images.

Lohman Technologies develops HomECG+, an innovative patient-centric home electrocardiogram monitoring solution designed for atrial fibrillation (AFib) detection and remote cardiac monitoring. The platform enables patients to perform a 45-second ECG test from any location globally, with data automatically transmitted to healthcare providers for clinical follow-up. HomECG+ integrates seamlessly with existing electronic medical records (EMR) and remote patient monitoring (RPM) platforms, bridging the gap between intermittent and continuous cardiac monitoring. The company focuses on exceeding industry standards for ease of use, data quality, and diagnostic accuracy. Lohman Technologies serves healthcare providers seeking improved access to real-time cardiac data and patients requiring convenient, non-invasive arrhythmia surveillance. Recent partnerships include strategic collaborations with Salvo Health to expand comprehensive remote gastrointestinal care capabilities.

INFINITT Healthcare is a global enterprise imaging software and services company headquartered in Seoul, South Korea, with operations spanning 56 countries. Founded in 2002, INFINITT specializes in Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and vendor-neutral imaging solutions for healthcare institutions. The company has deployed over 6,500 installations across hospitals, imaging centers, and specialty practices. INFINITT's core product portfolio includes INFINITT PACS 7.0, a web-based diagnostic viewer with AI-enabled reading workflows; INFINITT Cardiology Suite for cardiovascular and nuclear medicine imaging; INFINITT Digital Pathology Solution (IDPS) for quantitative histopathology analysis and remote consultation; INFINITT RT PACS for radiotherapy treatment planning and management; and Versity Dental platform for dental imaging in academic settings. The company emphasizes interoperability, cloud-based and on-premise deployment options, multi-disciplinary team collaboration tools (INFINITT MDT), and integrated electronic health record connectivity. INFINITT combines in-house R&D with customer-driven customization, lifecycle support, and IT security compliance to address radiology, cardiology, pathology, dental, and veterinary imaging workflows.

ATCOR Medical is a cardiovascular diagnostics company specializing in vascular biomarker monitoring through their SphygmoCor technology platform. The company develops clinical-grade software and hardware systems for non-invasive vascular assessment, central blood pressure measurement, and arterial stiffness analysis. Primary product is the SphygmoCor XCEL System, a digital vascular biomarker monitoring platform designed for clinical practice, academic research, and clinical trials. The company offers XCEL V1.3 base software installation, XCEL Secure Data Option (Part 11 compliant for regulated environments), and calibration kit software for annual system maintenance. ATCOR serves hospitals, clinics, research institutions, and clinical trial organizations globally. The company maintains offices in the USA (Naperville, Illinois), Australia (Sydney), and China (Shanghai), with an authorized distributor network. Technical support and software downloads are managed through their conneqthealth.com platform. Products are positioned for cardiovascular risk assessment and vascular health monitoring in both clinical and research settings.

Aidoc is a healthcare AI software company founded in 2016, providing clinical decision support solutions built on its proprietary aiOS™ platform. The company delivers AI-powered medical imaging analysis and clinical intelligence tools across radiology, cardiology, neurovascular, and vascular care specialties. Aidoc's algorithms automatically analyze medical imaging (primarily CT scans) to detect acute pathologies, identify incidental findings, and prioritize critical cases for rapid clinical intervention. The platform integrates with hospital workflows to improve notification time-to-treatment, enhance care team coordination, and optimize patient management across departments. Serving over 1,600 medical centers globally and analyzing imaging for approximately 45 million patients annually, Aidoc enables healthcare systems to cover approximately 75% of their patient populations with AI-assisted clinical decision support. Key clinical applications include stroke detection and door-to-puncture time reduction, pulmonary embolism prioritization, cardiac disease measurement, and vascular pathology management.

Marrek, Inc. is a leading provider of advanced cardiac imaging and analysis technologies for atrial fibrillation (AFib) treatment planning. The company operates Merisight, a proprietary image analysis service that leverages non-invasive cardiac MRI to quantify left atrium tissue damage and scar formation in AFib patients. By providing physicians with precise pre-ablation tissue mapping and post-ablation scar analysis, Merisight enables personalized treatment selection and improves ablation success rates beyond the current 50% baseline. The service integrates seamlessly with existing ablation mapping systems and includes protocol optimization, secure image sharing, expert processing, and comprehensive clinical support. Marrek's mission is to transform AFib treatment outcomes through data-driven decision support and tissue characterization.

MIR (Medical International Research S.p.A.) is an Italian medical device manufacturer with over 30 years of experience specializing in spirometry, oximetry, and cardiology solutions for respiratory and cardiovascular health management. The company operates in more than 100 countries and offers an integrated portfolio spanning professional clinical-use devices for hospitals and medical centers, as well as personal-use smartphone-compatible smart devices for home monitoring and proactive health management. MIR's regulatory credentials include FDA clearance for the United States, NMPA (China), ANVISA (Brazil), COFEPRIS (Mexico), Health Canada, and other international certifications, ensuring compliance with the highest quality standards. The company is internationally recognized for patented product designs and maintains constant investment in research and development. MIR's product lines include spirometers (Spirobank series, Spirodoc, Spirolab variants), oximeters (Smart One Oxi), and the Cardionica cardiology line. Software offerings include MIR Spiro Platinum, a comprehensive desktop/laptop platform for spirometry and oximetry data management, integrated with EMR/EHR systems and compliant with ATS/ERS guidelines. The company also supplies accessories, consumables, and turbine components. MIR serves pulmonologists, allergists, occupational health professionals, and institutional buyers including the UK's National Health Service (NHS). Manufacturing and service capabilities include device calibration, technical support, developer program access for OEM/ODM partnerships, and an established dealer network.

FHC, Inc. is a specialized medical device manufacturer based in Bowdoin, Maine, founded in 1970. The company focuses on neuroscience and neurosurgery solutions, particularly cranial microtargeting and neuromodulation. FHC designs and manufactures microelectrodes, electrode positioning systems, stereotactic platforms, and surgical planning software for both clinical and research applications. Their clinical product line includes the Guideline 5 Neuromodulation System, STarFix Stereotactic Platforms, STar Microdrive System, and WayPoint Navigation software for surgical planning. The research division offers NeuroCraft microelectrodes and insertion tubes for neurophysiology studies. FHC's solutions support therapeutic interventions including deep brain stimulation, ablation, resection, and treatment of movement disorders such as Parkinson's Disease, epilepsy, dystonia, and essential tremor. The company also provides stereoelectroencephalography (SEEG) equipment and operates Greenville Neuromodulation Services for DBS research and surgeon training. With approximately 170 employees and estimated annual revenue of $42.6 million, FHC serves neurosurgical centers and research institutions globally.

Aerotel Medical Systems is a global provider of remote patient monitoring and telemedicine solutions specializing in 12-lead ECG cardiac monitoring. The company manufactures portable, user-friendly ECG devices combined with cloud-based call center software and transtelephonic transmission capabilities for real-time patient data transfer via Internet, cellular, or telephone networks. Aerotel's product portfolio includes the HeartView 12L (professional handheld 12-lead ECG), HeartView P12/8i (Bluetooth-enabled personal ECG recorder), and HeartView P12/8 Mobile (home monitoring device with cellular modem and voice assistance). The company serves ambulance services, hospitals, telemedicine providers, and home monitoring programs globally. Aerotel's HeartView P12/8 has demonstrated clinical efficacy in published peer-reviewed research showing reduced in-hospital mortality when deployed by ambulance services. The company has successfully completed large-scale national projects, including equipping Hungary's national ambulance service (OMSZ) with ECG monitoring capabilities. Products incorporate voice-guided protocols to enable non-medical personnel to obtain hospital-grade ECG recordings. The company emphasizes one-stop integration support from solution design through implementation and ongoing operations. Founded in 1998, Aerotel maintains global headquarters in Holon, Israel, with international distribution through medical device distributors and service partners.

Wellysis Corp. is a digital health company specializing in wearable ECG monitoring and remote cardiac surveillance solutions. The company manufactures and distributes the S-Patch line, a patch-type ECG device powered by Samsung Smart Health Processor, designed as a replacement for traditional Holter monitors. The S-Patch ecosystem comprises four integrated components: (1) S-Patch Wear—a lightweight, wearable biosignal collection device available in standard (Ex) and extended (ExL) formats; (2) S-Patch App—a mobile application for real-time data monitoring compatible with both iOS and Android; (3) S-Patch Physician Web—a cloud-based reading and analysis platform with comprehensive ECG report generation; and (4) S-Patch AI—algorithmic decision-support functionality integrated across the platform. The company also offers SDK and API interoperability solutions for healthcare system integration. Wellysis received FDA 510(k) clearance in September 2023 and has established partnerships with major healthcare institutions, including Samsung Electronics, Kangbuk Samsung Hospital, and clinical organizations in the US and India. The platform targets hospitals, clinics, cardiac monitoring centers, and telehealth service providers. Recent strategic partnerships include collaborations with Medicalgorithmics S.A. and HeartcoR Solutions, expanding distribution in clinical trial and remote monitoring markets. The company is headquartered in South Korea with active US market presence.

Smartsound Corporation is a Seoul-based medical technology company specializing in AI-powered sound-based diagnostic solutions. Founded in 2011, the company has developed proprietary edge artificial intelligence technology that analyzes heart and lung sounds for disease diagnosis. Since 2021, Smartsound has collaborated with 12 leading Korean university hospitals to collect and analyze clinical data, securing AI diagnostic technologies capable of identifying 5 types of lung diseases and 5 types of heart diseases. The company offers a comprehensive portfolio of AI-enabled stethoscope products—including the SKEEPER R1 (hospital-grade), SKEEPER H1 (telemedicine/homecare), SKEEPER P1 (wearable patch for continuous monitoring), SM-300 (non-face-to-face telemedicine), and WITH A PET (veterinary cardiac assessment)—all featuring hardware-embedded AI, cloud data storage, Bluetooth connectivity, and telemedicine integration. Products support diagnosis, monitoring, and early detection of respiratory infections and cardiac conditions across clinical, home healthcare, and veterinary markets.

Elucid Bioimaging develops FDA-cleared cardiovascular imaging analytics software specializing in quantitative plaque assessment from coronary CT angiography (CCTA). The company's flagship product, PlaqueIQ™, employs CT Virtual Histology™ technology to characterize arterial plaque composition non-invasively, leveraging algorithms trained and validated against ground-truth histopathology. PlaqueIQ quantifies and classifies plaque morphology into calcified, non-calcified matrix, and lipid-rich necrotic core (LRNC) components, delivering patient-, vessel-, and lesion-level analysis with high correlation to ex vivo histology (r=0.87–0.99 across plaque types). The software integrates into clinical PACS workflows via DICOM-wrapped PDFs and interactive browser-based reports, enabling physicians to assess coronary and carotid atherosclerosis risk and guide medical versus interventional treatment decisions. Elucid holds FDA 510(k) clearance (K183012, December 2018) and has achieved Category I CPT coding and broad CMS reimbursement as of January 2026. The company also develops FFRCT (fractional flow reserve CT) technology under regulatory pathway. Served markets include cardiology, interventional cardiology, radiology, and cardiovascular research. Clinical validation includes partnership with CVPath Institute and peer-reviewed publications in major cardiovascular literature.

POWERbreathe International Ltd is a world leader in evidence-based respiratory muscle training devices and technology. The company develops drug-free, clinically validated breathing training and testing systems used across medical and sports applications. POWERbreathe's Inspiratory Muscle Training (IMT) devices use resistance-based principles to strengthen respiratory muscles and are supported by over 200 independent medical and sports research studies. The company's newer Expiratory Muscle Training (EX1) series, launched in 2023, enables more forceful and powerful exhalation. Products are NHS-approved and have demonstrated clinical benefits including reduced blood pressure, improved breathing strength and stamina, enhanced exercise tolerance, and alleviation of breathlessness in patients with respiratory conditions. The ActiBreathe® mobile app with Smart Adaptor provides digital monitoring, personalized training protocols, and performance tracking. Applications span medical conditions (asthma, COPD, post-COVID recovery, neuromuscular disease), sports performance enhancement, fitness, and general respiratory health.